We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

This page features the latest news about the Adial Pharma share. Rodman & Renshaw maintains Adial stock Buy rating, $8 target Tuesday On Tuesday, Rodman & Renshaw reaffirmed their Buy rating and ...

With FDA confirmation, Adial is commencing manufacturing of clinical supplies for Phase 3 clinical program in 2025. Secured several foundational patents, strengthening IP portfolio in support of ...

This page features the latest news about the Adial Pharma stock. Rodman & Renshaw maintains Adial stock Buy rating, $8 target Tuesday On Tuesday, Rodman & Renshaw reaffirmed their Buy rating and $ ...

周二，在Adial制药公司（NASDAQ:ADIL）发布第四季度财报后，Rodman & Renshaw重申了对该公司的买入评级和8.00美元的目标价。分析师Brandon Folkes表示继续看好该股票，特别强调了该公司主要研发药物AD04（用于治疗酒精使用障碍AUD）的潜力。 Folkes指出，AD04在减少酒精 ...

GLEN ALLEN, Va. - Adial Pharmaceuticals, Inc. (NASDAQ:ADIL), a biopharmaceutical company specializing in addiction treatment with a current market capitalization of $5 million, has been granted a new ...

Information provided on Forbes Advisor is for educational purposes only. Your financial situation is unique and the products and services we review may not be right for your circumstances.

GLEN ALLEN, Va., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for ...